poisar

Stocks · News reference

CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds

BenzingaVandana Singh

CG Oncology reports Phase 3 data showing cretostimogene cuts bladder cancer recurrence risk by 68%, advancing two 2027 BLA filings.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — CG Oncology, Inc. (CGON)

    Filed: 2026-11-16 AccNo: 0001193125-26-462199 Size: 17 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits